

# Vivianne C G Tjan-Heijnen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4280088/publications.pdf>

Version: 2024-02-01

77  
papers

2,768  
citations

304743

22  
h-index

197818

49  
g-index

77  
all docs

77  
docs citations

77  
times ranked

5633  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR <sup>+</sup> /HER2 <sup>+</sup> advanced breast cancer patients: A study of the Dutch SONABRE Registry. <i>International Journal of Cancer</i> , 2022, 150, 124-131.  | 5.1  | 6         |
| 2  | The initial hormone receptor/HER2 subtype is the main determinant of subtype discordance in advanced breast cancer: a study of the SONABRE registry. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 331.   | 2.5  | 3         |
| 3  | Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2022, 61, 619-624.  | 1.8  | 0         |
| 4  | Abstract P3-03-21: Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: What do they mean?. <i>Cancer Research</i> , 2022, 82, P3-03-21-P3-03-21.   | 0.9  | 0         |
| 5  | Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. <i>Acta Oncologica</i> , 2022, 61, 591-596.   | 1.8  | 2         |
| 6  | Noninvasive Prenatal Test Results Indicative of Maternal Malignancies: A Nationwide Genetic and Clinical Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2426-2435.   | 1.6  | 23        |
| 7  | Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228. | 2.8  | 12        |
| 8  | Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor <sup>+</sup> Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2934-2945.  | 1.6  | 6         |
| 9  | Associations of hospital volume and hospital competition with short-term, middle-term and long-term patient outcomes after breast cancer surgery: a retrospective population-based study. <i>BMJ Open</i> , 2022, 12, e057301.   | 1.9  | 0         |
| 10 | Frequency and diagnostic outcome of bilateral recall at screening mammography. <i>International Journal of Cancer</i> , 2021, 148, 48-56.  | 5.1  | 1         |
| 11 | Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 571-581.   | 2.5  | 5         |
| 12 | Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 64.  | 17.0 | 61        |
| 13 | A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1742-1749.   | 1.0  | 5         |
| 14 | Evaluation of the Khorana, PROTECHT, and 5â€šNP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.   | 3.8  | 14        |
| 15 | Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 245-254.  | 2.5  | 3         |
| 16 | Additional Breast Cancer Detection at Digital Screening Mammography through Quality Assurance Sessions between Technologists and Radiologists. <i>Radiology</i> , 2020, 294, 509-517.  | 7.3  | 6         |
| 17 | The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 677-685.  | 2.5  | 1         |
| 18 | Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.   | 27.8 | 221       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. <i>Quality of Life Research</i> , 2020, 29, 3363-3374.  | 3.1  | 11        |
| 20 | Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands. <i>British Journal of Cancer</i> , 2020, 123, 325-332.  | 6.4  | 8         |
| 21 | The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102988.   | 4.4  | 25        |
| 22 | An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. <i>Acta Oncologica</i> , 2020, 59, 1123-1130.   | 1.8  | 3         |
| 23 | Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 675-685.  | 2.5  | 4         |
| 24 | Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2020, 59, 713-722.  | 1.8  | 5         |
| 25 | High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.   | 7.1  | 17        |
| 26 | Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program. <i>Radiology</i> , 2020, 294, 528-537.  | 7.3  | 9         |
| 27 | Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 77-86.   | 2.5  | 16        |
| 28 | A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. <i>Acta Oncologica</i> , 2020, 59, 895-903.  | 1.8  | 10        |
| 29 | Abstract P1-19-34: The role of hormone receptor (HR) status on initial treatment choices and outcomes for human epidermal growth factor receptor (HER)-2 positive advanced breast cancer: A study of the southeast Netherlands advanced breast cancer (SONABRE) registry. , 2020, , . |      | 1         |
| 30 | Characteristics of screen-detected cancers following concordant or discordant recalls at blinded double reading in biennial digital screening mammography. <i>European Radiology</i> , 2019, 29, 337-344.   | 4.5  | 3         |
| 31 | Population-based study of the effect of preoperative breast MRI on the surgical management of ductal carcinoma <i>in situ</i> . <i>British Journal of Surgery</i> , 2019, 106, 1488-1494.   | 0.3  | 15        |
| 32 | Predicting the extent of nodal involvement for node positive breast cancer patients: Development and validation of a novel tool. <i>Journal of Surgical Oncology</i> , 2019, 120, 578-586.  | 1.7  | 11        |
| 33 | The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study. <i>Diagnostic and Prognostic Research</i> , 2019, 3, 20.   | 1.8  | 1         |
| 34 | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1239.   | 3.7  | 9         |
| 35 | The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.   | 21.4 | 250       |
| 36 | Utility of diagnostic breast excision biopsies during two decades of screening mammography. <i>Breast</i> , 2019, 46, 157-162.  | 2.2  | 6         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Trends in frequency and outcome of high-risk breast lesions at core needle biopsy in women recalled at biennial screening mammography, a multiinstitutional study. <i>International Journal of Cancer</i> , 2019, 145, 2720-2727.       | 5.1  | 10        |
| 38 | Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. <i>International Journal of Cancer</i> , 2019, 145, 1325-1333.  | 5.1  | 8         |
| 39 | Pan-cancer whole-genome analyses of metastatic solid tumours. <i>Nature</i> , 2019, 575, 210-216.   | 27.8 | 722       |
| 40 | Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. <i>International Journal of Cancer</i> , 2019, 145, 274-283.  | 5.1  | 7         |
| 41 | Trends in treatment and overall survival among patients with proximal esophageal cancer. <i>World Journal of Gastroenterology</i> , 2019, 25, 6835-6846.  | 3.3  | 13        |
| 42 | Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. <i>Breast</i> , 2018, 38, 101-106.   | 2.2  | 8         |
| 43 | Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 26.  | 3.0  | 44        |
| 44 | Moving Breast Cancer Therapy up a Notch. <i>Frontiers in Oncology</i> , 2018, 8, 518.   | 2.8  | 63        |
| 45 | Frequency and characteristics of additionally detected ipsilateral breast lesions following recall at screening mammography. <i>Breast</i> , 2018, 42, 94-101.  | 2.2  | 0         |
| 46 | The Lymph Node and the Metastasis. <i>New England Journal of Medicine</i> , 2018, 378, 2045-2046.   | 27.0 | 19        |
| 47 | Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. <i>British Journal of Cancer</i> , 2018, 119, 357-363.  | 6.4  | 22        |
| 48 | Impact of the second reader on screening outcome at blinded double reading of digital screening mammograms. <i>British Journal of Cancer</i> , 2018, 119, 503-507.  | 6.4  | 20        |
| 49 | Incorporation of the technologist's opinion for arbitration of discrepant assessments among radiologists at screening mammography. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 143-149.                                    | 2.5  | 2         |
| 50 | Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). <i>Breast Cancer Research and Treatment</i> , 2018, 172, 413-423. | 2.5  | 13        |
| 51 | Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth. <i>Journal of Pathology</i> , 2018, 246, 447-458.  | 4.5  | 67        |
| 52 | Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 353-364.   | 2.5  | 39        |
| 53 | What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2155-2160.   | 1.5  | 4         |
| 54 | Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 133-138.            | 2.5  | 12        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. <i>Journal of the National Cancer Institute</i> , 2017, 109, .                                      | 6.3  | 19        |
| 56 | Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit. <i>Journal of Surgical Oncology</i> , 2017, 115, 243-249.                         | 1.7  | 62        |
| 57 | Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1502-1511.  | 10.7 | 119       |
| 58 | Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography. <i>BMC Cancer</i> , 2017, 17, 315.  | 2.6  | 10        |
| 59 | Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 555-563.   | 2.5  | 13        |
| 60 | Intestinal-type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment. <i>Head and Neck</i> , 2016, 38, 1564-1570.   | 2.0  | 35        |
| 61 | Type and Extent of Surgery for Screen-Detected and Interval Cancers at Blinded Versus Nonblinded Double-Reading in a Population-Based Screening Mammography Program. <i>Annals of Surgical Oncology</i> , 2016, 23, 3822-3830. | 1.5  | 3         |
| 62 | Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 471-483.                                    | 2.5  | 44        |
| 63 | Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. <i>Oncologist</i> , 2016, 21, 555-562.                               | 3.7  | 35        |
| 64 | A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 123-130.                     | 2.4  | 16        |
| 65 | The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. <i>Oncotarget</i> , 2016, 7, 29412-29419.                                       | 1.8  | 11        |
| 66 | Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium. <i>Oncologist</i> , 2015, 20, 856-863.                                 | 3.7  | 31        |
| 67 | Loneliness in patients with cancer: the first year after cancer diagnosis. <i>Psycho-Oncology</i> , 2015, 24, 1521-1528.   | 2.3  | 33        |
| 68 | The relation between depression, coping and health locus of control: differences between older and younger patients, with and without cancer. <i>Psycho-Oncology</i> , 2015, 24, 950-957.                                      | 2.3  | 54        |
| 69 | Breast cancer diagnosis and death in the Netherlands: a changing burden. <i>European Journal of Public Health</i> , 2015, 25, 320-324.   | 0.3  | 34        |
| 70 | Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays. <i>Laboratory Investigation</i> , 2015, 95, 833-842.   | 3.7  | 40        |
| 71 | CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. <i>Oncotarget</i> , 2015, 6, 19634-19646.   | 1.8  | 53        |
| 72 | Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. <i>Journal of the National Cancer Institute</i> , 2014, 106, .  | 6.3  | 73        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 507-514. | 2.5 | 192       |
| 74 | Prognostic Impact of Isolated Tumor Cells and Micrometastases in Axillary Lymph Nodes of Breast Cancer Patients. <i>Breast Disease</i> , 2010, 31, 107-113.   | 0.8 | 10        |
| 75 | The Breast Cancer Sentinel Node Dilemma: What to do with Isolated Tumor Cells and Micrometastases?. <i>Breast Disease</i> , 2010, 31, 61-63.  | 0.8 | 0         |
| 76 | Micrometastases and Isolated Tumor Cells in Breast Cancer Are Indeed Associated With Poorer Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, e140-e140.   | 1.6 | 10        |
| 77 | Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 290-296.                                    | 1.6 | 25        |